# Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration

> **NCT05941715** · PHASE4 · COMPLETED · sponsor: **Medical University of Graz** · enrollment: 70 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept 40 MG/ML
- **DRUG:** Faricimab 120 MG/ML

## Key facts

- **NCT ID:** NCT05941715
- **Lead sponsor:** Medical University of Graz
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-04
- **Primary completion:** 2024-09-25
- **Final completion:** 2025-02-26
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05941715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05941715, "Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05941715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*